| If you are having problems viewing this message, use this link |
| |
 |
 |
> BioInvent and ThromboGenics Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402
> Stamford Doctors Help Test Experimental Cancer Drug
> Phosphagenics’ Further Refinements to Oxycodone Patch Design
> Addex Partner to Initiate Phase 2 Clinical Trial of ADX71149
> Medigene's Veregen Launched in Spain |
| |
| Headline Sponsor |
|
Med Ad News is your source for key performance metrics and extensive analytical reporting including Top Biotechnology Companies, Top Medicines, and Top Pharmaceutical Companies. Subscribe now to SAVE 30% and access this data at PharmaLive.com plus other valuable benefits, click here. |
| Headline Sponsor |
|
| |
| Cardiovascular |
| |
BioInvent and ThromboGenics Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402
From the PharmaLive.com News Archive - Jun. 05, 2012
BioInvent International and co-development partner ThromboGenics said the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban (Xarelto; Bayer), an oral anticoagulant. The study showed that the incidence of venous thromboembolism was similar with both drugs but patients receiving TB-402 had a significantly higher incidence of bleeding events.
  |
| |
Vivus Provides Update on Timing of European Decision for Qnexa
From the PharmaLive.com News Archive - Jun. 05, 2012
VIVUS announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rescheduled the decision process on the Marketing Authorization Application (MAA) for Qnexa, an investigational drug for the treatment of obesity.
|
| |
| Oncology |
| |
Stamford Doctors Help Test Experimental Cancer Drug
Stamford Advocate (CT) - Jun. 05, 2012
Stamford Hospital patient is among hundreds of women nationwide hoping to live longer with aggressive breast cancer due to an experimental drug administered in a clinical trial."This drug has basically put her in remission for almost a year," said Dr. Steven Lo, an oncologist at the hospital's Carl & Dorothy Bennett Cancer Center and co-investigator on its drug study.
|
| |
Galena Biopharma Announces NeuVax Improves Disease-Free Survival at 60-Month Median Follow-Up
From the PharmaLive.com News Archive - Jun. 05, 2012
Galena Biopharma targeted oncology treatments addressing major unmet medical needs to advance cancer care, updated NeuVax(E75) results at a physician panel on Monday, June 5, 2012 during the American Society of Clinical Oncology 2012 Annual Meeting in Chicago, Illinois.
|
| |
| Pain & Inflammation |
| |
Phosphagenics’ Further Refinements to Oxycodone Patch Design
From the PharmaLive.com News Archive - Jun. 05, 2012
Melbourne drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) is pleased to provide a further update to its recent announcement on 23 May 2012. Phosphagenics’ researchers have identified and tested several adhesives that have produced superior in vitro results to the 3M TPM/oxycodone patch.
|
| |
Galapagos to Present GLPG0634 Phase II POC Results at EULAR
Marketwire - Jun. 05, 2012
Galapagos announced that it will give an oral presentation on 9 June 2012 at the EULAR Annual European Congress of Rheumatology. Galapagos will present the results from the Phase II Proof of Concept study for GLPG0634, a selective inhibitor of Janus kinase 1 (JAK1), in rheumatoid arthritis patients.
|
| |
| Central Nervous System |
| |
Addex Partner to Initiate Phase 2 Clinical Trial of ADX71149
From the PharmaLive.com News Archive - Jun. 05, 2012
Addex Therapeutics announced that Janssen Research & Development is initiating a multicenter, double-blind, Phase 2 study of ADX71149 in adults with major depressive disorder who are also suffering anxiety symptoms.
|
| |
Parkinson's Vaccine - Worldwide First Clinical Study in Vienna
From the PharmaLive.com News Archive - Jun. 05, 2012
The worldwide first clinical trial for the development of a Parkinson's vaccine has now been started by AFFiRiS AG. The vaccine called PD01A is directed against alpha-Synuclein, a protein considered causing the onset and progression of the disease, and is currently being tested on Parkinson´s patients in a Phase I trial.
|
| |
| Infectious Disease |
| |
Medigene's Veregen Launched in Spain
From the PharmaLive.com News Archive - Jun. 05, 2012
Medigene said its partner BIAL Industrial Farmacéutica, S.A. has started the launch of Veregen, for the treatment of genital warts, in Spain. Following Germany and Austria, Spain is the third European market where Veregen is available. In addition, Veregen is also being marketed in the United States.
|
|
|
|
Editor: Barbara Lempert, blempert@pharmalive.com
Advertising: Daniel Becker, daniel.becker@ubm.com,
Andrew McSherry, andrew.mcsherry@ubm.com,
Sandra Baker, sandra.baker@ubm.com
Press Releases: editorial@pharmalive.com
Technical Support: support@pharmalive.com |
Visit Our Sites:
|
| |
|
|
|
|
 |
If you feel you have received this message in error, or wish to unsubscribe from this specific product only, please REMOVE ME.
Click here to view UBM Canon's privacy policy.
UBM Canon * 300 American Metro Blvd., Suite 125, Hamilton, NJ 08619 * United States * +1-609-759-7600 |
|